This article first appeared on GuruFocus. Adjusted Sales: Increased 4% to DKK 79.2 billion in Q3 2026, driven by volume growth across U.S. and International Operations, primarily in obesity. Adjusted Operating Profit: Increased 27% in Q3 2026, driven by sales growth and a favorable comparison base (partially offset by ~DKK 3.5 billion of one-time costs in Q3 2026). Adjusted Operating Profit (Absolute): DKK 32 billion generated in Q3 2026. Free Cash Flow: More than DKK 28 billion in Q3 2026; full-year 2026 outlook raised to DKK 6070 billion. Sales Growth by Unit: U.S. Operations +1%; International Operations +8%; Region UCAN +18%. Obesity Sales: Grew 22% in Q3 2026; International Operations obesity +24%.
Главную мысль мы показываем публично. Создайте бесплатный аккаунт, чтобы читать статью полностью, сохранять ее, обсуждать и связывать с рынками и OSINT-контекстом.